GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Current Deferred Revenue

ALMS (Alumis) Current Deferred Revenue : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alumis Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Alumis's current deferred revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

Alumis Current Deferred Revenue Historical Data

The historical data trend for Alumis's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Current Deferred Revenue Chart

Alumis Annual Data
Trend Dec22 Dec23
Current Deferred Revenue
- -

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

Alumis Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Alumis's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alumis Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.